Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) - Study Design and Baseline Characteristics.
Eder S, Leierer J, Kerschbaum J, Rosivall L, Wiecek A, de Zeeuw D, Mark PB, Heinze G, Rossing P, Heerspink HL, Mayer G. Eder S, et al. Among authors: heerspink hl. Kidney Blood Press Res. 2018;43(1):181-190. doi: 10.1159/000487500. Epub 2018 Feb 16. Kidney Blood Press Res. 2018. PMID: 29466797 Free article.
Composite renal endpoints: was ACCOMPLISH accomplished?
Heerspink HL, de Zeeuw D. Heerspink HL, et al. Lancet. 2010 Apr 3;375(9721):1140-2. doi: 10.1016/S0140-6736(10)60098-0. Epub 2010 Feb 18. Lancet. 2010. PMID: 20170949 No abstract available.
Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial.
Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, Pohl MA, de Zeeuw D, Heerspink HL, Rohde RD, Atkins RC, Reutens AT, Packham DK, Raz I; Collaborative Study Group. Lewis EJ, et al. Among authors: heerspink hl. Am J Kidney Dis. 2011 Nov;58(5):729-36. doi: 10.1053/j.ajkd.2011.06.020. Epub 2011 Aug 26. Am J Kidney Dis. 2011. PMID: 21872376 Clinical Trial.
Validation of Plasma Biomarker Candidates for the Prediction of eGFR Decline in Patients With Type 2 Diabetes.
Heinzel A, Kammer M, Mayer G, Reindl-Schwaighofer R, Hu K, Perco P, Eder S, Rosivall L, Mark PB, Ju W, Kretzler M, Gilmour P, Wilson JM, Duffin KL, Abdalla M, McCarthy MI, Heinze G, Heerspink HL, Wiecek A, Gomez MF, Oberbauer R; BEAt-DKD Consortium. Heinzel A, et al. Among authors: heerspink hl. Diabetes Care. 2018 Sep;41(9):1947-1954. doi: 10.2337/dc18-0532. Epub 2018 Jul 6. Diabetes Care. 2018. PMID: 29980527 Free PMC article.
Guidelines and clinical practice at the primary level of healthcare in patients with type 2 diabetes mellitus with and without kidney disease in five European countries.
Eder S, Leierer J, Kerschbaum J, Rosivall L, Wiecek A, de Zeeuw D, Mark PB, Heinze G, Rossing P, Heerspink HL, Mayer G. Eder S, et al. Among authors: heerspink hl. Diab Vasc Dis Res. 2019 Jan;16(1):47-56. doi: 10.1177/1479164118795559. Epub 2018 Sep 21. Diab Vasc Dis Res. 2019. PMID: 30238781 Free article.
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.
Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, Greene T, Tighiouart H, Matsushita K, Ballew SH, Sang Y, Vonesh E, Ying J, Manley T, de Zeeuw D, Eckardt KU, Levin A, Perkovic V, Zhang L, Willis K. Levey AS, et al. Among authors: heerspink hl. Am J Kidney Dis. 2020 Jan;75(1):84-104. doi: 10.1053/j.ajkd.2019.06.009. Epub 2019 Aug 28. Am J Kidney Dis. 2020. PMID: 31473020
Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program.
Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Li Q, Jardine M, Oh R, Heerspink HL, Perkovic V. Neuen BL, et al. Among authors: heerspink hl. J Am Soc Nephrol. 2019 Nov;30(11):2229-2242. doi: 10.1681/ASN.2019010064. Epub 2019 Sep 17. J Am Soc Nephrol. 2019. PMID: 31530577 Free PMC article. Clinical Trial.
Integrative analysis of prognostic biomarkers derived from multiomics panels helps discrimination of chronic kidney disease trajectories in people with type 2 diabetes.
Kammer M, Heinzel A, Willency JA, Duffin KL, Mayer G, Simons K, Gerl MJ, Klose C, Heinze G, Reindl-Schwaighofer R, Hu K, Perco P, Eder S, Rosivall L, Mark PB, Ju W, Kretzler M, McCarthy MI, Heerspink HL, Wiecek A, Gomez MF, Oberbauer R; BEAt-DKD Consortium. Kammer M, et al. Among authors: heerspink hl. Kidney Int. 2019 Dec;96(6):1381-1388. doi: 10.1016/j.kint.2019.07.025. Epub 2019 Aug 30. Kidney Int. 2019. PMID: 31679767 Free article.
45 results